273 related articles for article (PubMed ID: 29307242)
1. Technology of irreversible electroporation and review of its clinical data on liver cancers.
Cohen EI; Field D; Lynskey GE; Kim AY
Expert Rev Med Devices; 2018 Feb; 15(2):99-106. PubMed ID: 29307242
[TBL] [Abstract][Full Text] [Related]
2. Irreversible electroporation for colorectal cancer liver metastasis: a review.
Koethe Y; Wilson N; Narayanan G
Int J Hyperthermia; 2022; 39(1):682-687. PubMed ID: 35469520
[TBL] [Abstract][Full Text] [Related]
3. Irreversible Electroporation of Malignant Hepatic Tumors--Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up.
Dollinger M; Müller-Wille R; Zeman F; Haimerl M; Niessen C; Beyer LP; Lang SA; Teufel A; Stroszczynski C; Wiggermann P
PLoS One; 2015; 10(8):e0135773. PubMed ID: 26270651
[TBL] [Abstract][Full Text] [Related]
4. Irreversible electroporation in primary and metastatic hepatic malignancies: A review.
Lyu T; Wang X; Su Z; Shangguan J; Sun C; Figini M; Wang J; Yaghmai V; Larson AC; Zhang Z
Medicine (Baltimore); 2017 Apr; 96(17):e6386. PubMed ID: 28445252
[TBL] [Abstract][Full Text] [Related]
5. Irreversible Electroporation of Hepatic and Pancreatic Malignancies: Radiologic-Pathologic Correlation.
Gonzalez-Beicos A; Venkat S; Songrug T; Poveda J; Garcia-Buitrago M; Poozhikunnath Mohan P; Narayanan G
Tech Vasc Interv Radiol; 2015 Sep; 18(3):176-82. PubMed ID: 26365548
[TBL] [Abstract][Full Text] [Related]
6. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results.
Frühling P; Nilsson A; Duraj F; Haglund U; Norén A
Eur J Surg Oncol; 2017 Apr; 43(4):751-757. PubMed ID: 28109674
[TBL] [Abstract][Full Text] [Related]
7. Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins.
Distelmaier M; Barabasch A; Heil P; Kraemer NA; Isfort P; Keil S; Kuhl CK; Bruners P
Radiology; 2017 Dec; 285(3):1023-1031. PubMed ID: 28799842
[TBL] [Abstract][Full Text] [Related]
8. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
[TBL] [Abstract][Full Text] [Related]
9. Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre.
Freeman E; Cheung W; Kavnoudias H; Majeed A; Kemp W; Roberts SK
Cardiovasc Intervent Radiol; 2021 Feb; 44(2):247-253. PubMed ID: 33051707
[TBL] [Abstract][Full Text] [Related]
10. Irreversible Electroporation for Colorectal Liver Metastases.
Scheffer HJ; Melenhorst MC; Echenique AM; Nielsen K; van Tilborg AA; van den Bos W; Vroomen LG; van den Tol PM; Meijerink MR
Tech Vasc Interv Radiol; 2015 Sep; 18(3):159-69. PubMed ID: 26365546
[TBL] [Abstract][Full Text] [Related]
11. Irreversible electroporation for the ablation of liver tumors: are we there yet?
Charpentier KP
Arch Surg; 2012 Nov; 147(11):1053-61. PubMed ID: 23165618
[TBL] [Abstract][Full Text] [Related]
12. Ablation of perivascular hepatic malignant tumors with irreversible electroporation.
Kingham TP; Karkar AM; D'Angelica MI; Allen PJ; Dematteo RP; Getrajdman GI; Sofocleous CT; Solomon SB; Jarnagin WR; Fong Y
J Am Coll Surg; 2012 Sep; 215(3):379-87. PubMed ID: 22704820
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous ablation of peribiliary tumors with irreversible electroporation.
Silk MT; Wimmer T; Lee KS; Srimathveeravalli G; Brown KT; Kingham PT; Fong Y; Durack JC; Sofocleous CT; Solomon SB
J Vasc Interv Radiol; 2014 Jan; 25(1):112-8. PubMed ID: 24262034
[TBL] [Abstract][Full Text] [Related]
14. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).
Scheffer HJ; Vroomen LG; Nielsen K; van Tilborg AA; Comans EF; van Kuijk C; van der Meijs BB; van den Bergh J; van den Tol PM; Meijerink MR
BMC Cancer; 2015 Oct; 15():772. PubMed ID: 26497813
[TBL] [Abstract][Full Text] [Related]
15. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers?
Wu LM; Zhang LL; Chen XH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):117-124. PubMed ID: 30655073
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).
Bhutiani N; Philips P; Scoggins CR; McMasters KM; Potts MH; Martin RC
HPB (Oxford); 2016 Jul; 18(7):593-9. PubMed ID: 27346140
[TBL] [Abstract][Full Text] [Related]
17. Numerical workflow of irreversible electroporation for deep-seated tumor.
Gallinato O; de Senneville BD; Seror O; Poignard C
Phys Med Biol; 2019 Mar; 64(5):055016. PubMed ID: 30669121
[TBL] [Abstract][Full Text] [Related]
18. Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins - a case report.
Schoellhammer HF; Goldner B; Merchant SJ; Kessler J; Fong Y; Gagandeep S
BMC Cancer; 2015 Apr; 15():271. PubMed ID: 25886376
[TBL] [Abstract][Full Text] [Related]
19. Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis.
Nieuwenhuizen S; Dijkstra M; Puijk RS; Geboers B; Ruarus AH; Schouten EA; Nielsen K; de Vries JJJ; Bruynzeel AME; Scheffer HJ; van den Tol MP; Haasbeek CJA; Meijerink MR
Curr Oncol Rep; 2022 Jun; 24(6):793-808. PubMed ID: 35298796
[TBL] [Abstract][Full Text] [Related]
20. Liver Function Tests Following Irreversible Electroporation of Liver Tumors: Experience in 174 Procedures.
Froud T; Venkat SR; Barbery KJ; Gunjan A; Narayanan G
Tech Vasc Interv Radiol; 2015 Sep; 18(3):140-6. PubMed ID: 26365543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
